Reflections on Collaborations of a Computational Chemist with Medicinal Chemists and Other Scientists

  • Y. Connolly Martin
Conference paper
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 15)

Abstract

My responsibility is to lead a group that applies molecular modeling and quantitative structure—activity relationships (QSAR) concepts to make the process of drug discovery more efficient. Our emphasis is on applying known methods to problems of immediate interest to Abbott. However, since the methods to accomplish this are not perfected, we must continually evaluate and refine old methods and develop new ones. In this way we will be more able to answer the questions of key concern to the projects. This report will illustrate how interaction with other scientists has affected the accomplishments we have made.

Keywords

Dopamine Phenyl Macromolecule Catecholamine Sine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Borman S (1989) Software adds new dimension to structure searching. Chem Eng News 67: 28–32CrossRefGoogle Scholar
  2. Cramer RD III, Patterson DE, Bunce JD (1988) Comparative Molecular Field Analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110: 5959–5967Google Scholar
  3. DeNinno MR, Schoenleber R, MacKenzie R, Britton DR, Asin KE, Briggs C, Trugman JM, Ackerman M, Artman L, Bedzarz L, Bhatt R, Curzon P, Gomez E, Kang CH, Stittsworth J, Kebabian JW (1991) A-68930: a potent agonist selective for the dopamine D1 receptor. Eur J Pharmacol 199: 209–219PubMedCrossRefGoogle Scholar
  4. Goodford P (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28: 849–857PubMedCrossRefGoogle Scholar
  5. Kim K-H, Martin Y, Otis E, Mao J (1989) Inhibition of the 125I-labelled ristocetin binding to micrococcul luteus cells by the peptides related to bacterial cell wall mucopeptide precursors: quantitative structure-activity relationships. J Med Chem 32: 84–93PubMedCrossRefGoogle Scholar
  6. Martin YC (1990) Computer-aided design of potentially bioactive molecules by geometric searching with ALADDIN. Tetrahedron Comput Methodol 3: 15–25CrossRefGoogle Scholar
  7. Martin YC (1992) 3D database searching in drug design. J Med Chem 35:2145–2154Google Scholar
  8. Martin YC (1994) Molecular modeling in the design of potent and selective D1 dopaminergic agonists for potential use in parkinsonism. ACS Satellite TV Seminar: molecular modeling: the small-molecule approach. American Chemical Society, Washington DCGoogle Scholar
  9. Martin YC, DeLazzer J (in press) Family: a computer program that compares 3D structures based on interpoint distances: application to sorting hits from 3D database searching. J Comput Aided Mol DesignGoogle Scholar
  10. Martin YC, Kim KH (1984) Application of theoretical drug design methodology to a series of diuretics. Drug Inform J 18: 95–113Google Scholar
  11. Martin YC, Van Drie JH (1993) Identifying unique core molecules from the output of a 3D database search. Chemical structures 2. The international language of chemistry. Springer, Berlin Heidelberg New York, pp 315–326CrossRefGoogle Scholar
  12. Martin YC, Danaher EB, Weininger AM, Weininger D (1986) AIMM: 3-D models from 2-D MACCS connection tables—use of the GENIE target language to specify rules for structure building. Abstracts for Molecular Graphics Society meetingGoogle Scholar
  13. Martin YC, Danaher EB, May CS, Weininger D (1988) MENTHOR, a database system for three-dimensional structures and associated data searchable by substructure alone or combined with geometric properties. J Comput Aided Mol Design 2: 15–29CrossRefGoogle Scholar
  14. Martin YC, Kebabian JW, MacKenzie R, Schoenleber R (1991) Molecular modeling-based design of novel, selective, potent Dl dopamine agonists. QSAR: rational approaches on the design of bioactive compounds. Elsevier, Amsterdam, pp 469–482Google Scholar
  15. Martin YC, Kim K-H, Bures MG (1992) Computer-assisted drug design in the 21st century. Medicinal chemistry in the 21st century. Blackwell, Oxford, pp 295–317Google Scholar
  16. Martin YC, Bures MG, Danaher EA, DeLazzer J, Lico I, Pavlik PA (1993a) A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J Comput Aided Mol Design 7: 83–102CrossRefGoogle Scholar
  17. Martin YC, Lin CT, Wu J (1993b) Application of CoMFA to the design and structural optimization of D1 dopaminergic agonists. 3D QSAR in drug design. Theory methods and applications. Escom, Leiden, pp 643–660Google Scholar
  18. MedChem Software Manual Release 3.54 (1989) Claremont, California, Daylight Chemical Information SystemsGoogle Scholar
  19. Pearlman RS, Rusinko A III, Skell JM, Balducci R, McGarity CM (1988) Concord. St Louis, Missouri 63944, Tripos Associates, 1699 S. Hanley Road, Suite 303Google Scholar
  20. Plattner JJ, Lee CM, Horrom BW, Ours CW, Martin YC, Pernet AG (1982) Benzylamine diuretics. A unique class of (aryloxy)acetic acid derivatives. Abstract papers of the American Chemical Society, Sept 1982Google Scholar
  21. Schoenleber RW, Kebabian JW, Martin YC, DeNinno MP, Perner RJ, Stout DM, Hsiao C-NW, DiDomenico S Jr, DeBernardis JF, Basha FZ, Meyer MD, De B (1990) Dopamine agonists. US patent 4, 963–568Google Scholar
  22. Van Drie JH, Weininger D, Martin YC (1989) ALADDIN: an integrated tool for computer-assisted molecular design and pharmacophore recognition from geometric, steric, and substructure searching of three-dimensional molecular structures. J Comput Aided Mol Design 3: 225–251CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • Y. Connolly Martin

There are no affiliations available

Personalised recommendations